Clinical Research Directory
Browse clinical research sites, groups, and studies.
SIL as Maintenance Therapy in Multiple Myeloma
Sponsor: Navy General Hospital, Beijing
Summary
The goal of this phase 2 trial is to test the safety and efficacy of selinexor combined with ixazomib and lenalidomide as maintenance therapy in patients with multiple myeloma.
Official title: Selinexor Combined With Ixazomib and Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma
Key Details
Gender
All
Age Range
14 Years - Any
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2025-01-01
Completion Date
2030-01-01
Last Updated
2024-12-20
Healthy Volunteers
No
Conditions
Interventions
Selinexor combined with Ixazomib and Lenalidomide as Maintenance Therapy
Patients were treated by Selinexor (40mg po qw d1-28) combined with Ixazomib (4mg po on days 1, 8, and 15 in 28-day cycles) and Lenalidomide(10mg po qd d1-21) as Maintenance Therapy.